We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

50 hedge funds and large institutions have $19M invested in Karyopharm Therapeutics in 2025 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,166% more call options, than puts

Call options by funds: $1.61M | Put options by funds: $127K

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

38% more capital invested

Capital invested by funds: $13.7M → $19M (+$5.28M)

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

8.03% more ownership

Funds ownership: 43.04% → 51.07% (+8%)

2% more funds holding

Funds holding: 49 → 50 (+1)

Holders
50
Holders Change
+1
Holders Change %
+2.04%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
12
Reduced
7
Closed
10
Calls
$1.61M
Puts
$127K
Net Calls
+$1.48M
Net Calls Change
+$995K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$2.89M
2
Group One Trading
Group One Trading
Illinois
+$480K
3
JP Morgan Chase
JP Morgan Chase
New York
+$420K
4
SAM
Silverback Asset Management
North Carolina
+$343K
5
UBS Group
UBS Group
Switzerland
+$335K

Top Sellers

Rank Fund Capital Flow
1
PAI
Palo Alto Investors
California
-$668K
2
Millennium Management
Millennium Management
New York
-$115K
3
SC
Shay Capital
New York
-$95.1K
4
UOC
UBS O'Connor
Illinois
-$88.4K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$56.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$108K +$72K +14,668 +141%
Northern Trust
27
Northern Trust
Illinois
$81.5K – – –
GCP
28
GSA Capital Partners
United Kingdom
$60K +$68.2K +13,894 New
XT
29
XTX Topco
Cayman Islands
$56.3K +$64.1K +13,056 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$47.8K – – –
T. Rowe Price Associates
31
T. Rowe Price Associates
Maryland
$47K +$53.4K +10,886 New
Baird Financial Group
32
Baird Financial Group
Wisconsin
$45.4K +$51.7K +10,532 New
Simplex Trading
33
Simplex Trading
Illinois
$35K +$40.4K +8,233 New
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$32K +$29.3K +5,970 +409%
Citigroup
35
Citigroup
New York
$30.3K -$20 -4 -0.1%
Barclays
36
Barclays
United Kingdom
$23K – – –
TWC
37
TD Waterhouse Canada
Ontario, Canada
$14K – – –
TRCT
38
Tower Research Capital (TRC)
New York
$3.66K +$4.17K +850 New
Fidelity Investments
39
Fidelity Investments
Massachusetts
$3.3K +$1.17K +238 +45%
Osaic Holdings
40
Osaic Holdings
Arizona
$1.49K – – –
MLA
41
MB, Levis & Associates
Pennsylvania
$431 – – –
Raymond James Financial
42
Raymond James Financial
Florida
$388 +$442 +90 New
HI
43
Harbour Investments
Wisconsin
$366 – – –
FFO
44
Fortitude Family Office
Arizona
$349 +$397 +81 New
SS
45
SBI Securities
Japan
$319 – – –
AWM
46
Activest Wealth Management
Florida
$284 – – –
AF
47
Allworth Financial
California
$138 – – –
BGAI
48
Bruce G. Allen Investments
Colorado
$95 – – –
CIBC Private Wealth Group
49
CIBC Private Wealth Group
Georgia
$13 – – –
WBC
50
West Branch Capital
Massachusetts
$13 – – –
1
2
3

KPTI Hedge Fund Activity: Q2 2025 in Review

50 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2025, worth a combined $19M — up 38% from $13.7M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new KPTI positions and 10 closed out — a net gain of 1 holder — while 12 added to existing stakes and 7 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $2.89M. The largest seller was Palo Alto Investors, cutting an estimated $668K.

  • 50 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2025, up from 49 in Q1 2025.
  • Funds reported $19M of Karyopharm Therapeutics stock for Q2 2025, up 38% quarter-over-quarter.
  • 11 funds opened new Karyopharm Therapeutics positions in Q2 2025 and 10 closed out, a net change of +1 holder.
  • The largest Karyopharm Therapeutics buyer in Q2 2025 was T. Rowe Price Investment Management, an estimated $2.89M added.
  • The largest Karyopharm Therapeutics seller in Q2 2025 was Palo Alto Investors, an estimated $668K sold.

Based on aggregated 13F filings for Q2 2025.